Compare AbCellera Biologics Inc (ABCL) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Anheuser-Busch Inbev SA — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Anheuser-Busch Inbev SA trades at $79.4 (market cap $155.34B). The key difference: Anheuser-Busch Inbev SA is far larger — about 66.1× AbCellera Biologics Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.69% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BUD | |
|---|---|---|
Market Cap | $2.35B | $155.34B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $85.09 |
52-Week Low | $2.78 | $57.10 |
Enterprise Value | $1.99B | $216.53B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BUD trades at $79.74, down 1.95% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, maintains healthy profit margins (net income margin 11.9%), and shows improving cash flow trends. Recent news highlights premiumization strategies and digital expansion efforts to drive growth amid changing consumer preferences in the beverage-alcohol industry.
The outlook remains positive with analyst consensus pointing to 13% upside to the $90.08 price target. Key opportunities include continued earnings momentum and dividend yield support, while risks involve alcohol consumption trends and competitive pressures. The stock presents a compelling value proposition for investors seeking stable returns with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
